Observational Study to follow up patients enrolled in FIRST-Dx trial.

Conditions

Chemotherapy-naive adult patients with advanced cancer (GI, Lung, Breast, GYN, Melanoma)

Sadakatsu Ikeda, Junichi Matsubara, Kumi Mukai, Masahiro Yoshioka, Hidenori Kage et al. (13 authors)

Journal of Clinical Oncology2026-05-27

10.1200/jco.2026.44.16_suppl.3134

First‐Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1‐Year Follow‐Up of the <scp>FIRST</scp>‐Dx Study

Junichi Matsubara, Kumi Mukai, Tomohiro Kondo, Masahiro Yoshioka, Hidenori Kage et al. (14 authors)

Cancer Science2025-04-115 citations

10.1111/cas.70077

Molecularly matched therapies identified by comprehensive genomic profiling before the first-line setting to provide alternative treatment outcomes in patients with solid tumors: 1-year follow-up of the prospective FIRST-Dx study.

Ryuji Hayashi, Junichi Matsubara, Kumi Mukai, Masahiro Yoshioka, Hidenori Kage et al. (13 authors)

Journal of Clinical Oncology2024-06-011 citations

10.1200/jco.2024.42.16_suppl.3137

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Registered in FIRST-Dx trial, and underwent F1CDx. 2. Written informed consent.

Exclusion criteria

Exclusion criteria: 1. Withdrawal of informed consent. 2. Registered in FIRST-Dx trial, but failed in F1CDx. 3. Inappropriate case judged by investigators.

Design outcomes

Primary

Measure	Time frame
Overall Survival	—

Secondary

Measure	Time frame
1. The ratio of patients who actually receive molecular tumor board recommended therapy (MBRT) 2. Chemotherapy regimens in the subsequent lines of therapy 3. Progression-free survival in each subsequent line of therapy 4. Best Overall Response in each subsequent line of therapy 5. PFS ratio: MBRT/first-line therapy 6. PFS ratio_2: MBRT/prior therapy 7. One year suvival rate	—

Contacts

Public ContactJunichi Matsubara

Kyoto University Hospital

jmatsuba@kuhp.kyoto-u.ac.jp+81-75-751-3518

Outcome results